BenevolentAI S.A. (2XA.F)
| Previous close | 0.6020 |
| Open | 0.5780 |
| Bid | 0.5780 x N/A |
| Ask | 0.7060 x N/A |
| Day's range | 0.5780 - 0.6040 |
| 52-week range | 0.4460 - 2.0400 |
| Volume | |
| Avg. volume | 342 |
| Market cap | 78.319M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
BenevolentAI: Result of Annual General Meeting
LONDON, May 02, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery announces that all resolutions proposed at its Annual General Meeting held today were duly passed. The voting results will be made available shortly on the Company’s website (www.benevolent.com/investors/general-meetings/), where the full documentation regarding the AGM can also be found.
- Business Wire
BenevolentAI Provides an Update on Its Business Priorities
LONDON, April 23, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces an update on its business priorities.
- Business Wire
BenevolentAI: Publication of the Revised Agenda for the 2024 AGM
LONDON, April 17, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of the Revised Agenda for its Annual General Meeting set to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the "2024 AGM") (the "Revised Agenda").
